CHICAGO, Sept. 29, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis (NYSE: NVS), Pfizer (NYSE: PFE), AstraZeneca (NYSE: AZN), Roche (OTC: RHHBY) and Onyx Pharmaceuticals (Nasdaq: ONXX).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
Novartis Provides Afinitor Data
Novartis (NYSE: NVS) announced presentation of data from a pivotal late stage study (BOLERO-2) which evaluated the use of Afinitor in combination with Pfizer's (NYSE: PFE) Aromasin. The study evaluated postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies, Novartis' Femara or AstraZeneca's (NYSE: AZN) Arimidex.
The data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time without tumor growth, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to 6.9 months versus 2.8 months for Aromasin alone.
Afinitor plus Aromasin also significantly reduced the risk of cancer progression by 57% versus Aromasin. Novartis plans to file for the approval of Afinitor for the indication by year end.
Novartis also presented data from another phase III trial (EXIST-2) testing Afinitor in patients with non-cancerous kidney tumors (also known as angiomyolipomas) associated with tuberous sclerosis complex (TSC). The study met its primary endpoint of kidney tumor response rate. 42% of patients on Afinitor experienced a response versus 0% on placebo.
TSC is a genetic disorder which can lead to formation of tumors in vital organs like the brain (SEGA) and kidney. Up to 80% of patients with TSC have kidney tumors which is the lead cause of morbidity and mortality in adult TSC patients.
In July this year Novartis presented data from another late stage study of Afinitor in patients with TSC which demonstrated that Afinitor led to reduction in SEGA tumors too. The study showed that in more than one-third of the patients taking Afinitor, the size of the SEGA tumors was reduced by 50% or greater versus 0% on placebo.
Afinitor is currently marketed for the treatment of advanced renal cell carcinoma (kidney cancer) after an anti-VEGF therapy like Roche's (OTC: RHHBY) Avastin, Pfizer's Sutent or Onyx Pharmaceuticals'(Nasdaq: ONXX) Nexavar, in the US and EU. Afinitor is also approved for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin in the US and EU.
Afinitor is marketed in the US and approved in the EU (trade name: Votubia) for the treatment of subependymal giant cell astrocytomas (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).
Moreover, Afinitor is studied under late-stage trials for many other cancer types, like diffuse large B cell lymphoma, gastric cancer, hepatocellular carcinoma (HCC).
Our Recommendation
Currently, we have a Neutral recommendation on Novartis. The company carries a Zacks #3 Rank (Hold rating) in the short run. Though pleased with Novartis' wide range of products and its efforts to diversify further, as is evident by the acquisition of eye-care company Alcon, we prefer to remain on the sidelines due to the imminent patent cliff faced by the company.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
Share this article